# US 2012/0252800 A1 · Bicyclic thiazoles as allosteric modulators of mglur5 receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252800 A1
- Document ID: US20120252800A1
- Status: Published application
- Kind: A1
- Application number: 13/516,968
- Filed: 2010-12-16
- Published: 2012-10-04
- Earliest claimed: 2009-12-18
- Assignees: Janssen Pharmaceutica NV
- Inventors: Gregor James MacDonald; Gary John Tresadern; Andrés Avelino Trabanco-Suárez; Joaquin Pastor-Fernández
- Web page: https://patentgrep.com/patent/US20120252800A1

## CPC

- C07D 277/60: condensed with carbocyclic rings or ring systems
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.

## Claims

### Claim 1

A compound of formula (I)
or a stereoisomeric form thereof,
wherein
X is selected from CH2 and NR2;
A is selected from the group consisting of 1,2-ethanediyl; 1,2-ethenediyl; and 1,2-ethynediyl;
R1 is selected from the group consisting of phenyl; phenyl substituted with 1 or 2 halo substituents; pyridinyl; and pyridinyl substituted with 1 or two halo substituents;
or R1-A together is 3,4-dihydro-2H-1,4-benzoxazin-7-yl optionally substituted with methyl;
R2 is selected from the group consisting of hydrogen; methyl; methoxyethyl; aryl; benzyl; and benzyl wherein the phenyl part is substituted with 1 or 2 halo substituents;
wherein aryl is phenyl, optionally substituted with 1 or 2 substituents selected from the group consisting of methyl, methoxy, cyano, fluoro, chloro, trifluoromethyl and trifluoromethyloxy;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein
X is selected from CH2 and NR2;
A is selected from the group consisting of 1,2-ethanediyl; 1,2-ethenediyl; and 1,2-ethynediyl;
R1 is selected from the group consisting of phenyl; phenyl substituted with 1 or 2 halo substituents; pyridinyl; and pyridinyl substituted with 1 or two halo substituents;
or R1-A together is 3,4-dihydro-2H-1,4-benzoxazin-7-yl optionally substituted with methyl;
R2 is selected from the group consisting of hydrogen; methyl; methoxyethyl; benzyl; and benzyl wherein the phenyl part is substituted with 1 or 2 halo substituents;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein
X is selected from CH2 and NR2;
A is selected from the group consisting of 1,2-ethenediyl; and 1,2-ethynediyl;
R1 is selected from the group consisting of phenyl; phenyl substituted with 1 or 2 halo substituents; pyridinyl; and pyridinyl substituted with 1 or two halo substituents;
or R1-A together is 3,4-dihydro-2H-1,4-benzoxazin-7-yl optionally substituted with methyl;
R2 is selected from the group consisting of hydrogen; methyl; methoxyethyl; benzyl; and benzyl wherein the phenyl part is substituted with 1 or 2 halo substituents;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein
X is selected from CH2 and NR2;
A is selected from the group consisting of 1,2-ethenediyl; and 1,2-ethynediyl;
R1 is selected from the group consisting of phenyl; pyridinyl; and pyridinyl substituted with 1 or two fluoro substituents;
or R1-A together is 3,4-dihydro-2H-1,4-benzoxazin-7-yl optionally substituted with methyl;
R2 is selected from the group consisting of hydrogen; methyl; methoxyethyl; benzyl; and benzyl wherein the phenyl part is substituted with 1 or 2 fluoro substituents;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein
X is selected from CH2 and NR2;
A is selected from the group consisting of 1,2-ethenediyl; and 1,2-ethynediyl;
R1 is selected from the group consisting of phenyl; pyridinyl; and pyridinyl substituted with 1 or two fluoro substituents;
or R1-A together is 3,4-dihydro-2H-1,4-benzoxazin-7-yl optionally substituted with methyl;
R2 is selected from the group consisting of hydrogen; methyl; methoxyethyl; and benzyl;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

A compound according to claim 1, selected from the group consisting of
5,6-dihydro-2-(phenylethynyl)-7(4H)-benzothiazolone;
2-[(5-fluoro-3-pyridinyl)ethynyl]-5,6-dihydro-7(4H)-benzothiazolone;
6,7-dihydro-2-(phenylethynyl)-thiazolo[5,4-c]pyridin-4(5H)-one;
6,7-dihydro-5-methyl-2-(phenylethynyl)-thiazolo[5,4-c]pyridin-4(5H)-one;
5,6-dihydro-2-[(E)-2-phenylethenyl]-7(4H)-benzothiazolone;
5,6-dihydro-2-(2-phenylethyl)-7(4H)-benzothiazolone;
2-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5,6-dihydro-1,3-benzothiazol-7(4H)-one;
5,6-dihydro-2-(3-pyridinylethynyl)-7(4H)-benzothiazolone;
6,7-dihydro-5-(2-methoxyethyl)-2-(phenylethynyl)-thiazolo[5,4-c]pyridin-4(5H)-one; and
6,7-dihydro-2-(phenylethynyl)-5-(phenylmethyl)-thiazolo[5,4-c]pyridin-4(5H)-one;
or a pharmaceutically acceptable salt thereof.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A method for the treatment or prophylaxis of neurological or psychiatric disorders comprising administering a therapeutically effective amount of the compound of claim 1 to a patient suffering from such neurological or psychiatric disorders.

### Claim 9 (depends on 8)

The method of claim 8, wherein the neurological or psychiatric disorders are selected from schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified; psychosis associated with dementia, major depressive disorder, dysthymic disorder, premenstrual dysphoric disorder, depressive disorder not otherwise specified, bipolar I disorder, bipolar II disorder, cyclothymic disorder, bipolar disorder not otherwise specified, mood disorder due to a general medical condition, substance-induced mood disorder, mood disorder not otherwise specified, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, acute stress disorder, post-traumatic stress disorder, mental retardation, pervasive developmental disorders, attention deficit disorders, attention-deficit/hyperactivity disorder, disruptive behaviour disorders, personality disorder of the paranoid type, personality disorder of the schizoid type, personality disorder of the schizotypical type, tic disorders, Tourette's syndrome, substance dependence, substance abuse, substance withdrawal, trichotillomania, and conditions wherein cognition is impaired, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, Lewy Body Dementia, dementia due to HIV disease, dementia due to Creutzfeldt-Jakob disease, amnestic disorders, mild cognitive impairment, age-related cognitive decline, feeding disorders such as anorexia and bulimia, and obesity.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1 and a pharmaceutically acceptable carrier.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A method of treatment comprising administering a therapeutically effective amount of:
i) a compound as defined in claim 1; and
ii) a mGluR5 orthosteric agonist,
for simultaneous, separate or sequential use in the prevention, treatment or prophylaxis of neurological and psychiatric disorders and diseases.
